Thursday, December 13, 2018 3:41:48 PM
From the paper the authors state: ''In addition, the treatment requires surgery for procurement of a tumor from which to generate TILs, and the generation of high numbers of TILs takes approximately four to six weeks. In the present trial, patients underwent surgery and 29 patients received treatment (Appendix Fig A1, online only).
Another limitation is the patient-to-patient variability in the HPV reactivity of TILs and the infused cell product. Consistent with reports by others, we that TILs from a number of patients possessed no HPV reactivity or low HPV reactivity (Fig 2A and 2B, Appendix Fig A1, online only). In the administered T cells, the frequency of HPV reactivity ranged from ≤0.1 to 31%, median 5% (Fig 2A) and the magnitude of IFNg release ranged from ≤0.1 to 5.6 ng/ml, median 0.2 ng/ml (Fig 2B).
One strategy to circumvent surgery and generate a more consistent HPV oncoprotein-targeted cell product may be to administer HPV-specific T cells that are propagated and enriched ex vivo from peripheral blood. Another strategy may be to administer peripheral blood T cells that are genetically engineered ex vivo to target an HPV oncoprotein with a T cell receptor. We are presently testing this strategy in an active clinical trial with gene engineered T cells that target HPV16 E7 (NCT02858310)''
http://clincancerres.aacrjournals.org/content/early/2018/12/05/1078-0432.CCR-18-2722
Recent IOVA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:56:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:54:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:53:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 11:52:10 PM
- Iovance Biotherapeutics to Present at Upcoming Conferences • GlobeNewswire Inc. • 09/03/2024 09:00:18 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 09:16:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 09:10:32 PM
- Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024 • GlobeNewswire Inc. • 08/08/2024 08:01:32 PM
- Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024 • GlobeNewswire Inc. • 07/29/2024 08:01:00 PM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/19/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 12:01:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 12:01:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/18/2024 12:00:18 AM
- Iovance Biotherapeutics Submits Marketing Authorization Application to European Medicines Agency for Lifileucel in Advanced Melanoma • GlobeNewswire Inc. • 06/28/2024 11:00:00 AM
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 06/21/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:03:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 10:00:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 09:15:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 12:07:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 12:05:43 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 12:04:19 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:01:02 PM
- Iovance Biotherapeutics to Present at Upcoming Conferences and Events • GlobeNewswire Inc. • 05/24/2024 08:01:00 PM
- Iovance Biotherapeutics Announces Clinical Data in Frontline Advanced Melanoma at ASCO 2024 Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:00:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM